Ultragenyx Pharmaceutical (RARE) FCF Margin (2016 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported FCF Margin for 11 consecutive years, with 145.59% the latest figure, recorded in Q1 2026.

• In Q1 2026, FCF Margin fell 2544.0% year-over-year to 145.59%; the TTM figure through Mar 2026 stood at 75.11% (down 665.0% YoY), while the FY2025 annual figure was 70.13%, up 647.0% from the prior year.
• FCF Margin eased to 145.59% in Q1 2026 per RARE's latest filing, from 48.61% in the prior quarter.
• Across five years, FCF Margin topped out at 40.45% in Q4 2023 and bottomed at 187.28% in Q1 2022.
• Historically, FCF Margin has averaged 105.01% across 5 years, with a median of 120.12% in 2023.
• Annual changes were most pronounced in 2022 — FCF Margin plunged 16047 bps — and 2023, when it jumped 13955 bps.
• Ultragenyx Pharmaceutical's FCF Margin stood at 180.0% in 2022, then soared by 78 bps to 40.45% in 2023, then sank by 31 bps to 53.13% in 2024, then gained by 9 bps to 48.61% in 2025, then slumped by 199 bps to 145.59% in 2026.
• Business Quant data shows RARE's FCF Margin at 145.59% in Q1 2026, 48.61% in Q4 2025, and 57.96% in Q3 2025.